Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
New England Journal of Medicine · 09.11.2023 · 389 (19) · 1778-1789
DOI: 10.1056/nejmoa2309863 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift New England Journal of Medicine, erschienen am 09.11.2023. Verfasst von Michiel S van der Heijden und 24 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam (M.S.H.); Medical Oncology, Genitourinary Section, Dana-Farber Cance…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Cisplatin, Gemcitabine. Die Arbeit wurde bisher 517-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bristol-Myers Squibb.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam (M.S.H.); Medical Oncology, Genitourinary Section, Dana-Farber Cancer Institute, Harvard Medical School, Boston (G.S.); the Department of…
Förderung
- NCI NIH HHS
- Bristol-Myers Squibb
Zitieren
APA
van der Heijden, M. S., Sonpavde, G., Powles, T., Necchi, A., Burotto, M., Schenker, M., Sade, J. P., Bamias, A., Beuzeboc, P., Bedke, J., Oldenburg, J., Chatta, G., Ürün, Y., Ye, D., He, Z., Valderrama, B. P., Ku, J. H., Tomita, Y., Filian, J., …, & CheckMate 901 Trial Investigators (2023). Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma. New England Journal of Medicine, 389(19), 1778-1789. https://doi.org/10.1056/nejmoa2309863
Vancouver
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma. New England Journal of Medicine. 2023;389(19):1778-1789. doi:10.1056/nejmoa2309863
BibTeX
@article{vanderHeijden2023,
author = {van der Heijden, Michiel S and Sonpavde, Guru and Powles, Thomas and Necchi, Andrea and Burotto, Mauricio and Schenker, Michael and Sade, Juan Pablo and Bamias, Aristotelis and Beuzeboc, Philippe and Bedke, Jens and Oldenburg, Jan and Chatta, Gurkamal and Ürün, Yüksel and Ye, Dingwei and He, Zhisong and Valderrama, Begoña P and Ku, Ja Hyeon and Tomita, Yoshihiko and Filian, Jeiry and Wang, Lily and Purcea, Daniela and Patel, Miraj Y and Nasroulah, Federico and Galsky, Matthew D and CheckMate 901 Trial Investigators, CheckMate 901 Trial Investigators},
title = {Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {19},
pages = {1778--1789},
doi = {10.1056/nejmoa2309863}
}
EUVIMED